This litigation has concluded and we are proud to report that our clients' claims have been successfully resolved. The amounts of all individual client recoveries are confidential, both by settlement agreement and by attorney-client privilege. MLG is no longer accepting cases involving this product.
Pradaxa® is an anti-blood-clotting drug that was approved in October 2010 by the FDA for treatment of patients with atrial fibrillation, or A-Fib as it is commonly known, not caused by cardiac valve deficiencies. A-Fib occurs when the atrial chambers of the heart (the smaller, upper chambers) beat in an irregular fashion so that they are rhythmically out of sync with the lower, larger chambers of the heart – the ventricles. A-Fib can be caused by numerous conditions. Pradaxa® has also been approved to prevent the development of blood clots, deep vein thrombosis (DVT) and pulmonary embolisms (PE) in patients who have undergone hip replacement surgery and to reduce the risk of recurrence of DVT and PE in patients who were previously treated.
Since its introduction in the US, there have been numerous reports of bleeding injuries, most notably hemorrhages, associated with the use of Pradaxa®. Pradaxa® had been on the market for five (5) years before a rescue agent, Praxbind®, was manufactured and sold that could reverse the anticoagulant effect of the drug. Even with the new rescue agent, the bleeding risk posed by Pradaxa® is not eliminated. Learn more about these bleeding injuries, in particular hemorrhagic strokes which can lead to death and disability by clicking here.
This litigation has concluded and we are proud to report that our clients' claims have been successfully resolved. The amounts of all individual client recoveries are confidential, both by settlement agreement and by attorney-client privilege. MLG is no longer accepting cases involving this product.